MedTrace Logo

Cortisol in the Treatment of Phobias

NCT00451750 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-01-12

No results posted yet for this study

Summary

The aim of this prospective, double-blind, placebo-controlled, randomized study is to investigate if glucocorticoid treatment, in combination with exposure therapy, helps to reduce phobic fear in patients with phobia.

Conditions

  • Phobia

Interventions

DRUG

Cortisol

20 mg for 3 times

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Dominique JF de Quervain, MD, Prof. · University of Zurich

  • Frank Wilhelm, Prof. · University of Basel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00451750 on ClinicalTrials.gov